{"id":2157,"date":"2017-06-02T17:19:19","date_gmt":"2017-06-02T11:49:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2157"},"modified":"2021-07-24T12:56:46","modified_gmt":"2021-07-24T07:26:46","slug":"the-business-cocktail-25","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25","title":{"rendered":"Tesaro\u2019s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fea8f158185\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fea8f158185\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25\/#Tesaro_and_its_new_med_Zejula_are_on_the_block_but_bidders_arent_rushing_in\" >Tesaro and its new med Zejula are on the block, but bidders aren&#8217;t rushing in<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25\/#Mylan_lowballed_Medicaid_on_EpiPen_by_127B\" >Mylan lowballed Medicaid on EpiPen by $1.27B<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25\/#Ohio_sues_drugmakers_for_marketing_fraud\" >Ohio sues drugmakers for marketing fraud<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25\/#ATUM_Horizon_Discovery_Announce_cross-license_agreement\" >ATUM, Horizon Discovery Announce cross-license agreement<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Tesaro_and_its_new_med_Zejula_are_on_the_block_but_bidders_arent_rushing_in\"><\/span>Tesaro and its new med Zejula are on the block, but bidders aren&#8217;t rushing in<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That\u2019s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med launched soon after at a price of $118,000 per year, which Tesaro touted as lower than its head-to-head rivals in ovarian cancer, AstraZeneca\u2019s Lynparza and Clovis Oncology\u2019s Rubraca. Analysts have pegged Zejula, or niraparib, as one of 2017\u2019s biggest launches, with 2022 sales of $1.9 billion. That\u2019s an enticing prospect for bigger companies looking to beef up their oncology businesses, but that very fact could make it an expensive prospect, too. Thanks to a big stock runup since Tesaro rolled out top-line Zejula data last July, the company\u2019s market value as of Thursday morning was $8 billion. Tesaro has requested offers from a variety of potential bidders over the past few weeks\u2014but they also say potential acquirers aren\u2019t exactly falling over themselves to pursue a deal. Price is potentially one reason, obviously. Another? Would-be buyers might be waiting for the American Society of Clinical Oncology meeting this weekend, where AstraZeneca will present data on Lynparza and Tesaro will post data on a Zejula combination with Merck&#8217;s blockbuster PD-1 therapy Keytruda. Still another reason for the supposedly lukewarm interest: Pfizer&#8217;s $14 billion deal for Medivation\u2014and its PARP med talazoparib\u2014has come in for criticism lately.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Mylan_lowballed_Medicaid_on_EpiPen_by_127B\"><\/span>Mylan lowballed Medicaid on EpiPen by $1.27B<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Mylan quickly agreed to a $465 million settlement with the U.S. government last fall in a move to put some of its EpiPen problems in the past. Now, it appears that figure is far short of taxpayer harm resulting from the injector\u2019s misclassification on Medicaid, news that comes as the deal has yet to be finalized. The Department of Health and Human Services\u2019 Office of Inspector General reports that EpiPen\u2019s Medicaid misclassification cost taxpayers $1.27 billion from 2006 to 2016, far exceeding the U.S. government\u2019s settlement agreement with the drugmaker. Under heavy scrutiny for years of price hikes on the lifesaving epinephrine injection, Mylan struck a deal with the government to resolve fresh allegations of Medicaid misclassifications back in October. Pushing to learn more about the misclassification, Sen. Grassley on Wednesday said Mylan still isn\u2019t cooperating with the investigation. Mylan is withholding communications between it and the Centers for Medicare and Medicaid Services, which notified the company several times about the misclassification, according to the senator.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Ohio_sues_drugmakers_for_marketing_fraud\"><\/span>Ohio sues drugmakers for marketing fraud<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">After seeing drug overdoses become the state\u2019s leading cause of accidental deaths, officials in Ohio have had enough. In a new lawsuit filed on Wednesday, Ohio Attorney General Mike DeWine is going after Teva, Allergan, Johnson &amp; Johnson, Purdue and Endo for alleged \u201cfraudulent marketing practices\u201d on powerful opioid painkillers. Ohio\u2019s 101-page lawsuit says the pharma companies, individually and together, broke pharma marketing rules and \u201chelped unleash\u201d an opioid epidemic that has had \u201cfar-reaching financial, social, and deadly consequences\u201d in the state. The companies did that, according to the suit, by spending millions to widely market the meds while downplaying risks. Similar to a host of other lawsuits filed against opioid makers, Ohio&#8217;s suit says that to push their painkillers, the companies borrowed a page from the &#8220;Big Tobacco playbook.&#8221; They worked to convince \u201ckey opinion leaders\u201d and professional societies of the benefits of opioids in treating chronic pain. For its part, Teva said it\u2019s reviewing the complaint and can\u2019t comment until that review is complete. Endo said it couldn\u2019t comment on ongoing litigation; Allergan also declined to comment.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"ATUM_Horizon_Discovery_Announce_cross-license_agreement\"><\/span>ATUM, Horizon Discovery Announce cross-license agreement<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">ATUM and Horizon Discovery have announced that they have signed a cross-license agreement for Horizon\u2019s CHO SOURCE platform and ATUM\u2019s vector technology to speed development of highly productive stable cell lines for drug development. ATUM has licensed Horizon\u2019s CHO SOURCE platform, including the Glutamine Synthetase (GS) Knock-Out CHO K1 (Chinese hamster ovary) line, and will use its proprietary Leap-In\u00ae Transposase Technology to offer cell line development services.\u00a0 Horizon has exclusively licensed a vector suite developed by ATUM for the CHO SOURCE platform, to provide a complete cell line solution to its customers. Together, these technologies enable expression of complex biologics for customers of both ATUM and Horizon. ATUM is also offering Horizon customers a no-fee evaluation license for the transposase system.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tesaro and its new med Zejula are on the block, but bidders aren&#8217;t rushing in Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That\u2019s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[919,717,710,920,345,711,11487,918,712,561,17531],"industry":[17225],"therapeutic_areas":[17227,17228],"class_list":["post-2157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-atum","tag-collaboration","tag-epipen","tag-horizon-discovery","tag-keytruda","tag-ma","tag-opioid","tag-opioid-epidemic","tag-pharma-industry","tag-tesaro","tag-zejula","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tesaro\u2019s Zejula; Mylan on EpiPen; Ohio sues drugmakers<\/title>\n<meta name=\"description\" content=\"Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesaro\u2019s Zejula; Mylan on EpiPen; Ohio sues drugmakers\" \/>\n<meta property=\"og:description\" content=\"Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-02T11:49:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"256\" \/>\n\t<meta property=\"og:image:height\" content=\"196\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tesaro\u2019s Zejula; Mylan on EpiPen; Ohio sues drugmakers","description":"Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25","og_locale":"en_US","og_type":"article","og_title":"Tesaro\u2019s Zejula; Mylan on EpiPen; Ohio sues drugmakers","og_description":"Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-06-02T11:49:19+00:00","article_modified_time":"2021-07-24T07:26:46+00:00","og_image":[{"width":256,"height":196,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25","name":"Tesaro\u2019s Zejula; Mylan on EpiPen; Ohio sues drugmakers","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","datePublished":"2017-06-02T11:49:19+00:00","dateModified":"2021-07-24T07:26:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Just ahead of the year\u2019s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-25#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","width":256,"height":196},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atum<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Collaboration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EpiPen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Horizon Discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">M&amp;A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">opioid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">opioid epidemic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tesaro<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zejula<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Atum<\/span>","<span class=\"advgb-post-tax-term\">Collaboration<\/span>","<span class=\"advgb-post-tax-term\">EpiPen<\/span>","<span class=\"advgb-post-tax-term\">Horizon Discovery<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">M&amp;A<\/span>","<span class=\"advgb-post-tax-term\">opioid<\/span>","<span class=\"advgb-post-tax-term\">opioid epidemic<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Tesaro<\/span>","<span class=\"advgb-post-tax-term\">Zejula<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 2, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 2, 2017 5:19 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2157"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2157\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1033"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2157"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2157"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}